Table 1_Detection rate of [99mTc]Tc-PSMA SPECT/CT in prostate cancer: a systematic review

Twenty-three studies involving 1,840 patients were included in this systematic review and meta-analysis. The analysis, authored by Domenico Albano and last updated in April 2026, reports a pooled detection rate of 79.7% for primary staging and 75.4% for biochemical recurrence restaging using [99mTc]Tc-PSMA SPECT/CT imaging.

Use Cases

• Benchmarking the diagnostic performance of SPECT/CT against PET/CT based on the reported detection rates.
• Analyzing the relationship between PSA value and detection rate as suggested in the results.
• Supporting health technology assessments for alternative prostate cancer imaging modalities.
• Informing clinical guidelines for prostate cancer staging and restaging in environments without PET/CT access.

Strengths

• Meta-analysis synthesizes results from 23 distinct studies.
• Includes data from 1,840 total patients.
• Provides specific pooled detection rates with 95% confidence intervals for two clinical scenarios.

Limitations

• Column-level documentation is absent; field semantics must be inferred after download.
• Row count is unknown, which may limit suitability assessment.
• The description notes significant statistical heterogeneity in the analyses.

Provenance

Source

Domenico Albano via figshare.

Collection Method

Systematic review and meta-analysis of literature from PubMed/MEDLINE, Scopus, and Cochrane libraries.

Time Range

null

Freshness

Last updated 2026-04-13 05:47:49; freshness should be verified.

Geography

null